Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Nov
21
2023
Voluntary Self-Disclosure of FCPA Violations Following Acquisition Avoids Corruption Charges Sheppard, Mullin, Richter & Hampton LLP
Jul
17
2020
Clearing the Air: FinCEN Guidance May Help Banks Find Their Way in the Field of Hemp Financing Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2024
Health-e Law Episode 8: What We Heard at HIMSS 2024 with Michael Orlando & Carolyn Metnick [Podcast] Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2021
FDA’s Action Plan for Artificial Intelligence: Highlights and Insights for Developers Sheppard, Mullin, Richter & Hampton LLP
Mar
8
2021
California Legislative Update: Employment-Related Bills on the Horizon Sheppard, Mullin, Richter & Hampton LLP
Nov
16
2010
Proposition 23's Failure Means Full Speed Ahead on AB 32 Sheppard, Mullin, Richter & Hampton LLP
Feb
9
2018
Temporal Proximity Is Not Enough: Third Circuit Nixes FCA/Anti-Kickback Suit For Failure To Link Alleged Scheme to Claims Sheppard, Mullin, Richter & Hampton LLP
Apr
30
2021
New York State Legalizes Recreational Marijuana: What Employers Need to Know Sheppard, Mullin, Richter & Hampton LLP
Jul
30
2013
Food and Drug Administration (“FDA”) Draft Guidance For Industry On Pre-Launch Activities Importation Requests: Dead On Arrival? Sheppard, Mullin, Richter & Hampton LLP
Aug
9
2013
Unusual Circumstances: California Supreme Court Upholds Limited Use of Future Conditions Baseline Under California Environmental Quality Act (CEQA) Sheppard, Mullin, Richter & Hampton LLP
Sep
17
2021
SAFE Banking Act of 2021: Where Are We on Cannabis Banking Change? Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2021
Health Law Policy Heading Into 2022 At The ABA Health Law Summit Sheppard, Mullin, Richter & Hampton LLP
Jan
10
2022
CMS’ Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Sheppard, Mullin, Richter & Hampton LLP
Jan
13
2022
Day Three Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2019
HIMMS19 Conference – Blockchain Symposium Recap Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2019
OH SNAP! Supreme Court to Take on Meaning of Key FOIA Exemption Sheppard, Mullin, Richter & Hampton LLP
Apr
12
2022
No April Fools: Starting April 1st, Cannabis Operators Face CEQA Compliance Requirements for State Licenses Sheppard, Mullin, Richter & Hampton LLP
Nov
11
2014
Amgen/Sandoz Disputes Will Clarify BPCIA (Biologics Price Competition and Innovation Act) Issues Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2014
Dole Defeats “All Natural Claims” for Sweet Victory Sheppard, Mullin, Richter & Hampton LLP
Jul
5
2022
Recap of AHLA’s Annual Meeting Sheppard, Mullin, Richter & Hampton LLP
Mar
4
2015
Ascertainability Saps Plaintiffs’ Energy in Dietary Supplement Class Action Sheppard, Mullin, Richter & Hampton LLP
Jun
13
2023
Don’t Forget Deception: FTC and Biometrics Sheppard, Mullin, Richter & Hampton LLP
Jul
13
2023
The Ninth Circuit Declares that Ambiguity can be Cured with Back Label Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2020
Key Health Care Provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) Sheppard, Mullin, Richter & Hampton LLP
Jul
27
2023
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Apr
9
2020
Update: Key FDA Actions for COVID-19 Devices and Therapies Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2020
As America Prepares to Return to Work, EEOC Approves Testing Employees for COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Nov
10
2023
From Good Reprint Practices to SIUU Communications: What Firms Need to Know Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins